Connect with us

Psilocybin

Psyched: First Australian Psych Company On Nasdaq, Utah’s Psychedelics Bill, LSD Vs. Psilocybin Study Unprecedented Results

On the legislative front of the psychedelics space, a new bill meant to study the therapeutic effects of psychedelic substances received full approval…

Published

on

On the legislative front of the psychedelics space, a new bill meant to study the therapeutic effects of psychedelic substances received full approval in both Utah chambers, standing out from among dozens of measures currently circulating in legislatures across several U.S. states.

Psychedelic science also took an important step forward with the publication of a new clinical trial that raises doubts about the believed differences between LSD and psilocybin, also known as the active compound in psychedelic mushrooms. The results could affect industry developments around both molecules.

A new biotech company working with psychedelics has listed on the Nasdaq. Incannex (NASDAQ: IXHL) is developing a pipeline of several molecules (mostly cannabinoids) as well as a program using psilocybin in the treatment of anxiety.

Utah Senate Says Yes To Psychedelics And Mental Health Bill, Sending It To Governor

The Utah Senate approved a psychedelic and mental health bill that would create a Mental Illness Psychotherapy Drug Task Force to study and make recommendations on the therapeutic potential of psychedelic drugs. The bill, which is now heading to the governor’s desk for a signature, would also establish possible regulations for the legal use of psychedelic drugs. Read the full story…

LSD And Magic Mushroom's Active Compound Appear To Have The Same Effects, New Study Finds

A new peer-reviewed study compared the effects of LSD and psilocybin, two substances currently standing as top molecules behind the recent psychedelic ...

Full story available on Benzinga.com

Read More

Trending